Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success

Eli Lilly’s Mounjaro and Zepbound sales surged 125% and 80% in Q1 2026, and the two GLP-1 drugs now account for nearly two-thirds of company sales. Management is using the temporary cash windfall to fund acquisitions, with 2026 deal activity already reaching $10 billion upfront across eight companies and potentially $25 billion including earnouts. The article is constructive on Lilly’s reinvestment strategy but highlights patent-expiry and competitive risks as its GLP-1 franchise matures.

Analysis

LLY is in the classic “supernormal cash flow” phase where the market usually over-credits durability and under-credits reinvestment risk. The key second-order effect is that GLP-1 economics are not just funding R&D; they are effectively financing a corporate option book on future therapeutic franchises, which should widen LLY’s strategic moat if even a few acquisitions convert into durable pipeline assets. That makes the stock less of a pure GLP-1 trade and more of a capital-allocation story, with management now using M&A as a bridge from a patent-concentrated earnings stream to a broader portfolio.

The competitive dynamic is more fragile than headline demand suggests. Oral GLP-1 adoption is likely to compress willingness-to-pay for injectables faster than the market models, because pills expand the addressable base through convenience rather than efficacy alone; that creates a risk that pricing power erodes before patent expiry. NVO’s product cadence also matters because a better-tolerated oral option can shift prescriber behavior within 2-4 quarters, even if LLY remains the efficacy leader. The biggest loser is not just NVO — it is the entire cluster of adjacent obesity-enablement suppliers if payer pushback accelerates after utilization spikes.

The market is probably underestimating the variance of LLY’s M&A program. Buying assets at the top of the cycle is defensible only if management can consistently acquire de-risked biology or platform capabilities at sub-portfolio returns; otherwise, the company risks swapping one concentration problem for another. In the next 6-18 months, the stock will likely trade on acquisition quality and oral GLP-1 share data more than on quarterly sales prints. That means the bull case is no longer about “more growth,” but about whether growth can be translated into a repeatable reinvestment engine before exclusivity risk becomes visible in forward estimates.

Key Decisions for Investors

• Stay long LLY, but treat it as a barbell: core equity plus protective puts 6-9 months out. Risk/reward is favorable if management compounds capital successfully, but downside expands sharply if one or two acquisitions disappoint and the market starts discounting post-patent earnings.
• Initiate a relative-value pair: long LLY / short NVO over 3-6 months. The trade favors the company with stronger current cash generation and better reinvestment optionality, while NVO faces higher sensitivity to oral transition and share recapture risk.
• Buy LLY on 3-5% post-acquisition pullbacks rather than momentum breakouts. The stock is likely to overreact to deal headlines; use those windows to accumulate only if the acquired assets are platform-expanding, not single-product tuck-ins.
• Avoid chasing broad obesity-exposed baskets into strength; instead, sell into rallies in suppliers with the highest GLP-1 beta. If payer scrutiny tightens or oral adoption accelerates, those names can re-rate down faster than the drugmakers.
• Monitor NVO oral launch metrics and payer formulary updates as a 60-120 day catalyst set. If oral uptake is strong, consider adding to the LLY/NVO pair; if uptake is weak, reduce the hedge and let LLY’s M&A optionality dominate.